In particular, indirect comparisons from the network analysis for survival further confirmed the findings of direct analysis and demonstrated that anti‐PD‐1 + CT was most likely to provide the longest OS, followed by anti‐PD‐L1 + anti‐angiogenesis + CT in patients with SCLC with LM. The gene discussed is PDCD1; the disease is small cell lung carcinoma.